Page last updated: 2024-12-10

cyproterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyproterone: An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5284537
CHEMBL ID142130
CHEBI ID50742
SCHEMBL ID51228
MeSH IDM0005524

Synonyms (49)

Synonym
(1r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1h)-one
2098-66-0
cyproteronum [inn-latin]
3'h-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1-beta,2-beta-dihydro-17-hydroxy-
cyproterone [inn:ban]
6-chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [german]
ciproterona [inn-spanish]
ciproterone [dcit]
cyproterone
cyproterone (inn)
D07766
ciproterona servycal (tn)
cyproteronum
ciproterona
6-chloro-17-hydroxy-1beta,2beta-dihydro-3'h-cyclopropa[1,2]pregna-4,6-diene-3,20-dione
6-chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron
CHEBI:50742 ,
nsc-758636
CHEMBL142130
acetyl-chloro-hydroxy-dimethyl-[?]one
NCGC00188960-01
bay94-8367
nsc 758636
6-chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron
unii-e61q31ek2f
e61q31ek2f ,
cas-2098-66-0
tox21_111415
dtxcid102873
dtxsid3022873 ,
6-chloro-17-hydroxy-1beta,2beta-dihydro-3'h-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione,
cyproterone [who-dd]
cyproterone acetate impurity f [ep impurity]
3'h-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 6-chloro-1,2-dihydro-17-hydroxy-, (1beta,2beta)-
cyproterone [mi]
ciproterona servycal
cyproterone [inn]
(1beta,2beta)-6-chloro-1,2-dihydro-17-hydroxy-3'h-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione
6-chloro-1,2-dihydro-17-hydroxy-3'h-cyclopropa[a]pregna-1,4,6-triene- 3,20-dione
SCHEMBL51228
6-chloro-17-hydroxy-1alpha,2alpha-methylene-4,6-pregnadiene-3,20-dione
DUSHUSLJJMDGTE-ZJPMUUANSA-N
(1s,2s,3s,5r,11r,12s,15r,16s)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.0^{2,8}.0^{3,5}.0^{12,16}]octadeca-7,9-dien-6-one
6-chloro-17-hydroxy-1a,2a-methylenepregna-4,6-diene-3,20-dione
(3as,3bs,3cs,5as,6r,8as,8br)-6-acetyl-10-chloro-6-hydroxy-3b,5a-dimethyl-3,3a,3b,3c,4,5,5a,6,7,8,8a,8b-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-2(2ah)-one
Q7381206
(2s,5r,15r,16s)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one
(1s,2s,3s,5r,11r,12s,15r,16s)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one
AKOS040744751

Research Excerpts

Overview

Cyproterone acetate (CPA) is a widely used drug in the treatment of advanced prostatic carcinoma. It is a steroidal anti-androgen with weak progestational activity that results in the partial suppression of pituitary gonadotropin. Cyproter one acetate is an effective and well-tolerated treatment for metastatic male breast cancer.

ExcerptReferenceRelevance
"Cyproterone acetate acts as an antiandrogen through competitive inhibition of the androgens at cellular level on the peripheral effectors. "( [Anti-androgens. Their use in dermatology].
Arevalo, A; Michelotti, M; Montero, ED, 1981
)
1.71
"Cyproterone acetate is a steroidal anti-androgen that blocks the androgen-receptor interaction and reduces serum testosterone through its weak anti-gonadotropic action. "( The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
de Voogt, HJ, 1992
)
2.07
"Cyproterone acetate is a progestational antiandrogen with potent antigonadotropic activity that results in rapid suppression of serum testosterone. "( Use of cyproterone acetate in prostate cancer.
Bruchovsky, N; Goldenberg, SL, 1991
)
2.18
"Cyproterone acetate (CPA) is a widely used drug in the treatment of advanced prostatic carcinoma. "( Severe hepatocellular dysfunction following cyproterone acetate therapy.
Hamid, S; Parys, BT; Thomson, RG, 1991
)
1.99
"Cyproterone acetate (CPA) is a synthetic progestogen which possesses antiandrogenic properties with some synandrogenic action."( [Effects of cyproterone acetate on mouse submandibular gland].
Ichikawa, M; Maruyama, S, 1989
)
1.38
"Cyproterone acetate is a steroidal antiandrogen with weak progestational activity that results in the partial suppression of pituitary gonadotropin. "( The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Bruchovsky, N; Coppin, CM; Goldenberg, SL; Rennie, PS, 1988
)
2.05
"Cyproterone acetate is an effective and well-tolerated treatment for metastatic male breast cancer."( Cyproterone acetate in the treatment of metastatic cancer of the male breast.
Lopez, M, 1985
)
2.43

Effects

Cyproterone acetate has a stronger inhibitory effect than megestrol acetate (MGA) and flutamide (FL) on the prostate and seminal vesicle of intact adult rats. In the United States it has only been approved as an orphan drug to treat severe hirsutism.

ExcerptReferenceRelevance
"Cyproterone acetate (CPA) has a stronger inhibitory effect than megestrol acetate (MGA) and flutamide (FL) on the prostate and seminal vesicle of intact adult rats. "( Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats.
el Etreby, MF; Habenicht, UF; Louton, T; Nishino, Y; Schröder, HG, 1987
)
2.12
"Cyproterone acetate has been used in Europe for many years, but in the United States it has only been approved as an orphan drug to treat severe hirsutism."( Antiandrogens in the treatment of acne and hirsutism.
Jurzyk, RS; Rose, LI; Spielvogel, RL, 1992
)
1
"Cyproterone acetate (CPA) has been discovered more than 25 years ago and it was the first antiandrogen suitable for clinical use. "( Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience.
Kalmus, J; Neumann, F, 1991
)
3.17
"Cyproterone acetate (CPA) has a stronger inhibitory effect than megestrol acetate (MGA) and flutamide (FL) on the prostate and seminal vesicle of intact adult rats. "( Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats.
el Etreby, MF; Habenicht, UF; Louton, T; Nishino, Y; Schröder, HG, 1987
)
2.12

Actions

ExcerptReferenceRelevance
"Cyproterone acetate may inhibit the steroidogenic parameters of the androgen-producing cell population of the adrenal cortex without testicular mediation."( Effect of cyproterone acetate on adrenal cortex of castrated mice.
Migally, N, 1979
)
1.38

Treatment

Cyproterone acetate in treatment of women exhibiting androgenization symptoms acts primarily by competitive suppression of the androgens in the target organs. Treatment with cy Proterone seems more effective in those patients with low-stage and low-grade prostatic cancer.

ExcerptReferenceRelevance
"Cyproterone acetate treatment induced a highly significant raise in plasma prolactin, a fact which may explain the less favourable clinical results in this group."( Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study.
Aakvaag, A; Nissen-Meyer, R; Sander, S, 1982
)
1.29
"Cyproterone acetate treatment was applied with good success by the authors to 52 patients with hirsutism. "( [Personality and the social significance of hirsutism].
Csömör, S; Gimes, R; Lux, E; Rusz, E, 1982
)
1.71
"Cyproterone acetate treatment did not affect the concentration of any element in rete testis fluid or serum."( The effects of cyproterone acetate on the elements in the intraluminal fluids of the testis and epididymis of the rat.
Howards, SS; Jenkins, AD; Lechene, CP, 1983
)
1.34
"Cyproterone treatment seemed more effective than medroxyprogesterone, with respect to both sexual development and evolution of the bone age/height age ratio or the predictable adult height."( [Precocious puberty in boys. Study of a series of 34 cases].
Blanco-Garcia, M; Canlorbe, P; Chaussain, JL; Job, JC, 1983
)
0.99
"Cyproterone acetate treatment does not change the salt-water balance or the plasma volume in such a way that the risk of congestive heart failure could be increased."( Effects of oestrogens, orchidectomy and cyproterone acetate on salt and water metabolism in carcinoma of the prostate.
Karlberg, BE; Varenhorst, E; Wallentin, L; Wranne, B, 1981
)
1.25
"Cyproterone acetate treatment, however, results in the cytological differentiation of this epithelium."( [Action of androgens and one anti-androgen on the genital ducts of young discoglosses. Early development of seminal vesicles and inhibition of mullerian ducts (author's transl)].
Huchon, D,
)
0.85
"Cyproterone acetate treatment of the animals influences in vitro the testosterone to androstenedione conversion but not the activity of 5alpha-reductase in the mouse kidney slices."( Effect of cyproterone acetate on the action and metabolism of testosterone in the mouse kidney.
Broulík, P; Stárka, L; Sulcová, J, 1976
)
1.38
"Cyproterone acetate in treatment of women exhibiting androgenization symptoms acts primarily by competitive suppression of the androgens in the target organs."( [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Huber, J; Schmidt, JB; Spona, J, 1986
)
1.12
"Cyproterone acetate treatment from 1 to 10 days resulted in a definitive reduction in the relative weights of all accessory sex organs studied and when injected from 11 to 20 days in epididymis and vas deferens."( Permanent changes in the functional development of accessory sex organs and in fertility in male mice after neonatal exposure to cyproterone acetate.
Berger, M; De Turckheim, M; Jean, C; Jean-Faucher, C; Veyssiere, G, 1985
)
1.2
"Treatment with cyproterone seems more effective in those patients with low-stage and low-grade prostatic cancer."( Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy--5-year follow-up.
Giberti, C; Giuliani, L; Martorana, G; Natta, G; Pescatore, D, 1980
)
0.86
"Treatment with cyproterone acetate at diestrus caused a decrease in the number of small follicles (less than 200 micrometer), freshly formed corpora lutea and the levels of estradiol-17beta in the ovary, suggesting inhibition of ovulation."( Evidence for a role of androgens in the growth and maturation of ovarian follicles in rats.
Datta, JK; Kumari, GL; Roy, S, 1978
)
0.6
"Treatment with cyproterone acetate significantly decreased TG/FFA cycling in perigenital (epididymal) tissue."( Sex difference in triglyceride/fatty acid substrate cycling of rat adipose tissue: indirect regulation by androgens.
Hansson, P; Nilsson-Ehle, P; Saggerson, D, 1991
)
0.62
"Treatment with cyproterone acetate (50-100 mg/day) in 26 girls resulted in arrest of breast development and suppression of menstruation, but a definite effect on growth was not documented."( Isosexual precocious puberty in girls.
De Bruyn, R; Grant, DB; Lyon, AJ, 1985
)
0.61

Toxicity

ExcerptReferenceRelevance
" Climacteric symptoms, Kupperman index scores and potential adverse progestogen effects were recorded before treatment and three times per month during therapy."( Progestogens: therapeutic and adverse effects in early post-menopausal women.
Christiansen, C; Marslew, U; Riis, B, 1991
)
0.28
" and, especially, the presence of previous cardiovascular disease represented adverse factors in the development of cardiovascular toxicity."( Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer tria
de Pauw, M; de Voogt, HJ; Pavone-Macaluso, M; Smith, PH; Suciu, S, 1986
)
0.52
" Conformal treatment planning spares adjacent normal tissues reducing treatment-related side effects and may permit safe dose escalation."( Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
Bidmead, M; Dearnaley, DP; Eeles, R; Gadd, J; Hall, E; Horwich, A; Huddart, RA; Lawrence, D; Nutting, CM; Warrington, A, 2005
)
0.33
"To review and evaluate the potential adverse effects of these oral contraceptives (OCP) to overweight women."( Pills-related severe adverse events: A case report in Taiwan.
Chang, HY; Chen, CH; Chen, HH; Chin, HY; Liu, WM, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" During the 4-10 hours following administration, carbon-14-CA in plasma disappeared with a half-life of 3 + or -1."( Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 micrograms ethinyloestradiol to 6 young women.
Dogs, G; Hümpel, M; Schulze, PE; Speck, U; Weiss, C; Wendt, H, 1977
)
0.52
" Cyproterone acetate was eliminated from the body with a half-life of about 1 1/2 days for men and about 2 days for women."( [Pharmacokinetics of cyproterone acetate in normal subjects after i.m. and oral application (author's transl)].
Jentsch, D; Schulz, V; Wendt, H, 1976
)
1.48
" By 10 hours post administration the plasma level had declined with a half-life of 7,9 +/- 2,5 hours (distribution and elimination)."( [Bioavailability and pharmacokinetics of 14C-cyproterone acetate after administration as a 50-mg tablet (author's transl)].
Jentsch, D; Kühne, G; Schulze, PE; Speck, U; Wendt, H, 1976
)
0.52

Compound-Compound Interactions

The effects of serum lipids and lipoproteins of 2 mg cyproterone acetate (CPA) given alone and in combination with 35 or 50 micrograms ethinyl estradiol (EE) were studied in 21 oophorectomized women in a study with a cross-over design.

ExcerptReferenceRelevance
" This 12-mo study was carried out to investigate the effects of orchiectomy, alone and in combination with testosterone, and of treatment with cyproterone acetate on pancreatic carcinogenesis in azaserine-treated rats and BOP-treated hamsters."( Effects of orchiectomy, alone or in combination with testosterone, and cyproterone acetate on exocrine pancreatic carcinogenesis in rats and hamsters.
de Jong, FH; Foekens, JA; Klijn, JG; Lamberts, SW; Meijers, M; van Garderen-Hoetmer, A; Visser, CJ; Woutersen, RA, 1992
)
0.72
" The four groups receiving hormone replacement therapy were given 2 mg estradiol valerate equivalents (E), either sequentially combined with 75 micrograms levonorgestrel (E/LNG), 10 mg medroxyprogesterone acetate (E/MPA), or 150 micrograms desogestrel (E/DG), or continuously combined with 1 mg cyproterone acetate (E/CPA)."( Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Christiansen, C; Haarbo, J; Hassager, C; Jensen, SB; Riis, BJ, 1991
)
0.46
"The metabolic effects of cyproterone acetate (2 mg) combined with a new dose level of ethinyl estradiol (35 micrograms) were studied over a one-year period in 31 patients presenting moderate clinical hyperandrogenism."( Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients.
Cathelineau, G; Fiet, J; Hardy, N; Martineau, I; Vexiau, P; Vexiau-Robert, D; Villette, JM, 1990
)
0.84
"This prospective randomized phase III trial compares orchidectomy as standard androgen-deprivative therapy of advanced (metastatic) prostatic cancer with treatment using the LHRH agonist Buserelin administered as nasal spray 3 daily doses of 400 micrograms, and combined with cyproterone acetate (CPA) 3 daily doses of 50 mg orally for 2 weeks initially to prevent flare-up of the disease, or continuously as complete androgen blockade."( Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
De Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, F; Studer, U; Sylvester, R, 1990
)
0.71
" In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (GnRH) agonist."( The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G, 1988
)
0.27
" Thirty-one male-to-female transsexuals, treated at least 3 months either with 100 mg CA alone or in combination with 50 micrograms ethinyloestradiol (EO)/day, were studied."( The effect of cyproterone acetate alone and in combination with ethinylestradiol on the hypothalamic pituitary adrenal axis, prolactin and growth hormone release in male-to-female transsexuals.
de Vries, CP; Gooren, LJ; van der Veen, EA, 1986
)
0.63
" A multicenter study was therefore done, in which two preparations containing CA in combination with ethinylestradiol (EE) were compared with a marketed combined oral contraceptive pill."( Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.
Carlborg, L, 1986
)
1.71
"The effects of serum lipids and lipoproteins of 2 mg cyproterone acetate (CPA) given alone and in combination with 35 or 50 micrograms ethinyl estradiol (EE) were studied in 21 oophorectomized women in a study with a cross-over design."( Effects of cyproterone acetate (CPA) on serum lipoproteins when administered alone and in combination with ethinyl estradiol (EE).
Crona, N; Enk, L; Lindberg, UB; Samsioe, G; Silfverstolpe, G, 1987
)
0.91
" In the first phase of the treatment it was administered in combination with cyproterone acetate (CyA) to counteract an early stimulatory effect until inhibition of gonadotrophin secretion was achieved."( Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience.
Ben-Zeev, Z; Kaufman, H; Kauli, R; Laron, Z; Lewin, RP; Pertzelan, A; Schally, AM; Schally, AV, 1984
)
0.73
" In this study, we investigated the effect of the antiestrogen tamoxifen and the antiandrogen cyproterone acetate in combination with the LH-RH agonist buserelin in 9 patients with unresectable pancreatic adenocarcinoma."( Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma.
Arnold, R; Havemann, K; Swarovsky, B; Wolf, M,
)
0.72

Bioavailability

ExcerptReferenceRelevance
"The bioavailability and pharmokinetics of cyproterone acetate (CA) were studied in 6 healthy young women."( Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 micrograms ethinyloestradiol to 6 young women.
Dogs, G; Hümpel, M; Schulze, PE; Speck, U; Weiss, C; Wendt, H, 1977
)
0.79
" Such effects depend not only on increased androgen production by the ovary or adrenal gland but also on the bioavailability of androgen to peripheral tissues."( Anti-androgens in gynaecological practice.
Franks, S; Reed, MJ, 1988
)
0.27
" Bioavailability after oral administration was nearly complete (88 +/- 20%)."( Pharmacokinetics of cyproterone acetate and its main metabolite 15 beta-hydroxy-cyproterone acetate in young healthy women.
Huber, J; Kuhnz, W; Schmidt, J; Spona, J; Täuber, U; Zeillinger, R, 1988
)
0.6
" Thus the distribution of synthetic steroids between various protein bound and nonprotein bound components in serum may influence their bioavailability at different target tissues."( Distribution and percentages of non-protein bound contraceptive steroids in human serum.
Hammond, GL; Lähteenmäki, P; Lähteenmäki, PL; Luukkainen, T, 1982
)
0.26
" Also it appears that individual differences in CPA bioavailability do not satisfactorily explain the lack of therapeutic response in about 30% of the cases."( Antiandrogens in the treatment of acne and hirsutism.
Hammerstein, J; Moltz, L; Schwartz, U, 1983
)
0.27
" The bioavailability of the active substance was complete following oral application."( [Bioavailability of cyproterone acetate after oral and intramuscular application in men (author's transl)].
Becker, H; Düsterberg, B; Klosterhalfen, H, 1980
)
0.58
" However, very little is known concerning the bioavailability and plasma levels of unmetabolized gestagens in the animal species used for chronic toxicity testing and pharmacological investigation."( Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys.
Düsterberg, B; Hümpel, M; Speck, U, 1981
)
0.49
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Cyproterone acetate produced a greater mean stimulation of the enzyme at concentrations less than approximately 25 muM. DES at a dosage of 3 mg/day carries a significantly higher risk of overall cardiovascular toxicity.

ExcerptRelevanceReference
" The dose-response curves of all the test agents expressed in terms of percentage inhibition were approximately parallel to each other."( Anti-androgen TSAA-291. I. Anti-androgenic effects of a new steroid TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives.
Masaki, T; Masuoka, M; Nakayama, R; Shimamoto, K, 1979
)
0.26
" Following low dosage cyproterone acetate (CA) therapy (mean daily dosage 65 mg/m2BSA) a beneficial effect on growth and skeletal maturation was observed."( Effect of cyproterone acetate (CA) on growth and endocrine function in precocious puberty.
Ilicki, A; Stahnke, N; Willig, RP, 1979
)
0.98
" The classification of the anti-androgens, their indications, side-effects, dosage schemes and results of treatment are reviewed."( [Clinical aspects of the anti-androgens].
Holtzhausen, GH, 1979
)
0.26
" With the dosage used (200-300 mg/day in the sexual precocity patients, 300-400 mg in the gynaecomastia patients) the changes in plasma hormone levels (LH, FSH, progesterone, estradiol, testosterone) were within a non significant range."( [A new antigonadotropin in the treatment of precocious puberty and pubertal gynaecomastia (author's transl)].
Frisch, H; Spona, J; Swoboda, W; Turnheim, E, 1977
)
0.26
" Dosage of DHT was varied from 500 mcg to 1 mg and time of injection was varied from concurrent with EB injection to 12 hours after."( Estrogen-induced sexual receptivity and localization of 3H-estradiol in brains of female mice: effects of 5 alpha-reduced androgens, progestins and cyproterone acetate.
Gray, HE; Jasper, TW; Luttge, WG; Sheets, CS, 1977
)
0.46
" The dose-response curves of the steroids differed, however, in that cyproterone acetate produced a greater mean stimulation of the enzyme at concentrations less than approximately 25 muM, whereas, at higher concentrations, cyproterone was the more effective inducer."( Cyproterone-mediated stimulation of delta-aminolevulinic acid synthetase in chick embryo liver cells.
Gidari, AS; Lane, SE; Levere, RD, 1976
)
1.93
" Prolonged hormonal and incorrect treatments, mainly for too high dosage and absence of association with progesterone, assumption of oestrogens, can cause the growth of mammary tumours."( [Male transsexualism and hormonal therapy: radiologic pictures of the breast].
Bocchini, R; Cavallotti, GP; Genovese, MG; Godano, A; Grassi, G; Massara, D, 1990
)
0.28
"5 years, the mean daily dosage 115 mg."( [Ambulatory treatment of sex offenders with cyproterone acetate (Androcur). A catamnestic study].
Battegay, R; Micheroli, R, 1985
)
0.53
" Six of the patients were treated with cyproterone acetate in a dosage of 50-100 mg daily."( [Cyproterone acetate in the treatment of post-orchiectomy flushing].
Hendriksen, ON; Jansen, JE, 1989
)
1.46
"In a study of low-dose oral contraceptives, it was found that the low dosage caused insignificant effects on glucose and lipid metabolism."( Metabolic effects of three new low-dose pills: a six-month experience.
Bertolotto, A; Fioretti, P; Fruzzetti, F; Giampietro, O; Melis, G; Miccoli, R; Navalesi, R; Orlandi, MC; Ricci, C, 1989
)
0.28
" The often discussed intrinsic estrogen activity of the antiestrogens was present only in the highest dosage tested of tamoxifen."( Antiestrogen and antiandrogen administration reduce bone mass in the rat.
Bauss, F; Feldmann, S; Lempert, UG; Minne, HW; Parvizi, S; Pfeifer, M; Ziegler, R, 1989
)
0.28
" Cyproterone acetate allows differentiated treatment according to the various grades of hirsutism by modification of dosage and application."( [The concept of the causal therapy of hirsutism].
Schmidt, JB, 1986
)
1.18
" Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne."( On therapeutic approaches to some special types of acne.
Rajka, G, 1985
)
0.27
"45 patients with recently detected prostatic cancer were treated with cyproterone acetate (CPA) at a dosage of 100 mg/die."( [Therapy of prostatic cancer with cyproterone acetate].
Maier, U, 1988
)
0.79
" Side-effects are frequent, possibly as a result of the high dosage used in this study."( Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer.
de Vries, EG; Dikkeschei, LD; Mulder, NH; Sleijfer, DT; van der Ploeg, E; Willemse, PH, 1988
)
0.55
" No differences between the 3 treatment arms were observed except for medroxy-progesterone acetate, which showed less therapeutic effect in the dosage used."( Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne, FM, 1988
)
0.27
" In conclusion, this simplified method is thought to be very valuable for studies on the pharmacokinetics of CPA and 15 beta-OH-CPA, and on the relationship between the CPA dosage and the therapeutic or side effects on adrenal and gonadal steroid production."( A reversed-phase high-performance liquid chromatographic method for the simultaneous determination of serum concentrations of cyproterone acetate and 15 beta-hydroxycyproterone acetate.
Saisho, S; Shimozawa, K; Yata, J; Yodo, K, 1988
)
0.48
" One should, however, be aware that Diane contains only 2 mg cyproterone acetate (CPA) and a better effect would most probably have been obtained using a higher dosage of CPA."( A comparative study of Aldactone and Diane in the treatment of hirsutism.
Djøseland, O; Lunde, O, 1987
)
0.51
" Results suggested that hormone-sensitive behavior and physiology were related to suprathreshold androgen differences in a dose-response fashion among virgin males."( Suprathreshold manipulations of testosterone and reproductive functioning in gonadally intact sexually experienced and inexperienced male rats.
Rupich, R; Taylor, GT; Weiss, J, 1985
)
0.27
" The dosage of the hormone, the time of the neonatal period, and differences in the animal strain, are considered influencing factors on this effect."( Some aspects of the mechanisms involved in steroid-induced sterility.
Arai, Y, 1972
)
0.25
" dosage ranged from 50 to 200 mg (in 2 cases 300 mg), and the length of treatment varied from 6 months to 4 1/2 years."( [Changes in the human testis during anti-androgen treatment: histological, morphological and enzyme-histochemical investigations on testicular biopsies].
Horn, HJ; Städtler, F, 1973
)
0.25
" A distinct modification of spermatogenesis and posttesticular sperm maturation processes cannot be demonstrated in the dosage range studied."( [Modification of fertility of the male by antiandrogens].
Hammerstein, J; Moltz, L; Neumann, F, 1980
)
0.26
" Thus it appears that CA has no untoward effect upon glucocorticoid secretion when given in high dosage for prolonged periods to hirsute women."( Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism.
Croxson, MS; Evans, MC; France, J; Holdaway, IM; Ibbertson, HK; Sheehan, A; Wilson, T, 1983
)
0.67
" The medium-dose regimen (total dosage per cycle: 192 mg of CPA) is more effective than the low-dose regimen (42 mg of CPA per cycle) in the treatment of patients with moderate hyperandrogenism who do not require the high-dose oral standard antiandrogen therapy (1000 mg of CP A per cycle)."( [Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study].
Kaiser, E; Moltz, L, 1984
)
0.6
" It has become evident that DES at a dosage of 3 mg/day carries a significantly higher risk of overall cardiovascular toxicity than does cyproterone acetate, but severe cardiovascular complications did not differ between treatment groups."( Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Schroeder, FH, 1984
)
0.47
" In four patients who showed progression of the angrogen-dependent signs (adrenarche), despite suppression of gonadotrophins, increasing the dosage of the LHRH analogue was ineffective and combined therapy with CyA was reinstituted in three of them because of accelerated growth and bone maturation."( Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience.
Ben-Zeev, Z; Kaufman, H; Kauli, R; Laron, Z; Lewin, RP; Pertzelan, A; Schally, AM; Schally, AV, 1984
)
0.5
" A high dosage "reverse sequential" therapy of 100 mg CPA on the 5th-14th days of the menstrual cycle and 40 mcg ethinyl estradiol (EE) on the 5th-25th days is used in severe cases."( [Clinical use of antiandrogens in the female].
Hammerstein, J; Moltz, L; Schwartz, U, 1980
)
0.26
"Cyproterone acetate was given to three healthy men in a dosage of 10 mg per day for 8-14 weeks."( Effects of low doses of cyproterone acetate on sperm morphology and some other parameters of reproduction in normal men.
Carlström, K; Fredricsson, B,
)
1.88
" Thus, the effects of CPA containing drug on the endometrium depend essentially on their type, dosage and mode of administration."( Effects of cyproterone acetate and ethinylestradiol on endometrial histology.
Klebe, U; Moltz, L; Pickartz, H, 1983
)
0.66
" These findings suggest that firstly, although low dosage CPA was able to induce changes in seminal analyses, azoospermia was present in only one out of 15 subjects exposed to the drug."( Use of low-dosage oral cyproterone acetate as a male contraceptive.
Wang, C; Yeung, KK, 1980
)
0.57
" Sperm motility also decreased dramatically at both dosage levels (to below 40% motility)."( Use of low-dosage oral cyproterone acetate as a male contraceptive.
Wang, C; Yeung, KK, 1980
)
0.57
" Experiments in which the time of administration of hCG +/- cyproterone was varied after PMSG priming suggested that cyproterone at a dosage of 25 mg/kg had a "rescuing" effect on follicles destined to become atretic for up to 96 hr after PMSG priming."( The role of androgens in follicular development in the ovary. I. A quantitative analysis of oocyte ovulation.
Ware, VC, 1982
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
androgen antagonistA compound which inhibits or antagonises the biosynthesis or actions of androgens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
17alpha-hydroxy steroidThe alpha-stereoisomer of 17-hydroxy steroid.
chlorinated steroidA steroid which is substituted with one or more chlorine atoms in any position.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency14.96310.000811.382244.6684AID686978
AR proteinHomo sapiens (human)Potency6.84970.000221.22318,912.5098AID743035; AID743040; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.13140.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.02570.000229.305416,493.5996AID743069; AID743075; AID743078
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.66820.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency15.84890.10009.191631.6228AID1346983
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (99)

Assay IDTitleYearJournalArticle
AID221868Compound was evaluated in vivo for antitumor activity against mammary adenocarcinoma 16/C after injecting the compound intravenously for total dose. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID75393Compound was evaluated in vivo for antitumor activity against Glasgow osteogenic sarcoma after injecting the compound intravenously for median tumor burden1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID101885Compound was evaluated in vivo for antitumor activity against M5076 after injecting the compound intraperitoneally for percent T/C1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID101412Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for tumor free survivors at an optimal dose of 200 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153696Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12) for tumor free survivors at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID37754Compound was evaluated in vivo for antitumor activity against B16 melanoma after injecting the compound intravenously for toxicity related death.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153227Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for total dose at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID153075Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for change in body weight at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID103096Compound was evaluated in vivo for antitumor activity against Lewis Lung cercinoma after injecting the compound intravenously for median tumor burden1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153083Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for median day of death at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID37614Compound was evaluated in vivo for antitumor activity against B16 melanoma after injecting the compound intravenously for change in body weight.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID221869Compound was evaluated in vivo for antitumor activity against mammary adenocarcinoma 16/C after injecting the compound intravenously for toxicity related death.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID75389Compound was evaluated in vivo for antitumor activity against Glasgow osteogenic sarcoma after injecting the compound intravenously for percent T/C1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID37744Compound was evaluated in vivo for antitumor activity against B16 melanoma after injecting the compound intravenously for total dose. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID102968Compound was evaluated in vivo for antitumor activity against Lewis Lung cercinoma after injecting the compound intravenously for percent T/C1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID75392Compound was evaluated in vivo for antitumor activity against Glasgow osteogenic sarcoma after injecting the compound intravenously for toxicity related death.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153699Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12) for total dose at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID75387Compound was evaluated in vivo for antitumor activity against Glasgow osteogenic sarcoma after injecting the compound intravenously for change in body weight.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID153687Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12) for % increase in life span at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID101262Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for % increase in life span at an optimal dose of 200 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID75388Compound was evaluated in vivo for antitumor activity against Glasgow osteogenic sarcoma after injecting the compound intravenously for optimal dose1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID37627Compound was evaluated in vivo for antitumor activity against B16 melanoma after injecting the compound intravenously for percent T/C1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID101889Compound was evaluated in vivo for antitumor activity against M5076 after injecting the compound intraperitoneally for toxicity related death.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID221865Compound was evaluated in vivo for antitumor activity against mammary adenocarcinoma 16/C after injecting the compound intravenously for change in body weight.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID101253Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for change in body weight at an optimal dose of 200 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID101891Compound was evaluated in vivo for antitumor activity against M5076 after injecting the compound intraperitoneally for median tumor burden1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID101421Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against L1210(935) for total dose at an optimal dose of 200 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID75391Compound was evaluated in vivo for antitumor activity against Glasgow osteogenic sarcoma after injecting the compound intravenously for total dose. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID153079Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for % increase in life span at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID153692Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12 for mortality range at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID221995Compound was evaluated in vivo for antitumor activity against mammary adenocarcinoma 16/C after injecting the compound intravenously for median tumor burden1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID39323Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 18 hours.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID101883Compound was evaluated in vivo for antitumor activity against M5076 after injecting the compound intraperitoneally for optimal dose1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID102967Compound was evaluated in vivo for antitumor activity against Lewis Lung cercinoma after injecting the compound intravenously for optimal dose1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153092Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for tumor free survivors at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID101887Compound was evaluated in vivo for antitumor activity against M5076 after injecting the compound intraperitoneally for total dose. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID37755Compound was evaluated in vivo for antitumor activity against B16 melanoma after injecting the compound intravenously for median tumor burden1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID101271Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for median day of death at an optimal dose of 200 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID176392Antiandrogenic activity as the dose required to inhibit testosterone propionate-induced rat ventral prostate weight gain in castrated immature rat by 50%.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID101404Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for mortality range at an optimal dose of 200 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID221866Compound was evaluated in vivo for antitumor activity against mammary adenocarcinoma 16/C after injecting the compound intravenously for optimal dose1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID102966Compound was evaluated in vivo for antitumor activity against Lewis Lung cercinoma after injecting the compound intravenously for change in body weight.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID221867Compound was evaluated in vivo for antitumor activity against mammary adenocarcinoma 16/C after injecting the compound intravenously for percent T/C1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID37617Compound was evaluated in vivo for antitumor activity against B16 melanoma after injecting the compound intravenously for optimal dose1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153683Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12 for change in body weight at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID39322Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 1 hour.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID103095Compound was evaluated in vivo for antitumor activity against Lewis Lung cercinoma after injecting the compound intravenously for toxicity related death.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID103094Compound was evaluated in vivo for antitumor activity against Lewis Lung cercinoma after injecting the compound intravenously for total dose. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153087Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for mortality range at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153689Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12 for median day of death at an optimal dose of 75 mg/kg/injection1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,588)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901305 (82.18)18.7374
1990's202 (12.72)18.2507
2000's45 (2.83)29.6817
2010's28 (1.76)24.3611
2020's8 (0.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 87.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index87.15 (24.57)
Research Supply Index7.52 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index160.17 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (87.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials157 (9.32%)5.53%
Reviews118 (7.01%)6.00%
Case Studies111 (6.59%)4.05%
Observational1 (0.06%)0.25%
Other1,297 (77.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (35)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females [NCT04964193]24 participants (Actual)Interventional2019-03-12Completed
A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of Polycystic Ovary Syndrome [NCT03264638]Phase 2315 participants (Anticipated)Interventional2016-10-01Recruiting
Study to Evaluate Physician Awareness and Knowledge of Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Monotherapies in Europe: an Observational Post-Authorisation Joint Safety Study (Safe-CAM) [NCT04925180]600 participants (Actual)Observational2021-10-18Completed
Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris [NCT00752635]Phase 448 participants (Actual)Interventional2004-09-30Completed
Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin [NCT01103518]Phase 4100 participants (Anticipated)Interventional2009-12-31Active, not recruiting
The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography [NCT01065220]Phase 432 participants (Actual)Interventional2010-02-28Completed
Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma [NCT01011751]Phase 3311 participants (Actual)Interventional2004-04-30Completed
OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women [NCT02744131]100 participants (Anticipated)Interventional2016-05-31Recruiting
Prospective Observational Non-interventional Study of Correlation of Treatment With Androcur, Disease Stage, Testosterone Level, Age With Sexual Function and Erectile Dysfunction (Measured by IIEF-5 Validated Questionnaire) [NCT00919022]194 participants (Actual)Observational2009-08-31Terminated
A Prospective Controlled Randomized Multicenter Trial to Evaluate the Effect of a Structurized Multifactorial Behavior Modifying Consultation and Support Programme DiaNe for People With Diabetic Nephropathy [NCT00782847]Phase 3125 participants (Actual)Interventional2004-07-31Completed
"Effect of Cyproterone Acetate / Ethinyl Estradiol Combination on Periodontal Tissue and High Sensitivity C- Reactive Protein Levels in Women With Polycystic Ovary Syndrome Having Gingivitis." [NCT05657171]50 participants (Anticipated)Observational2022-12-12Not yet recruiting
Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy Plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis [NCT00849082]Phase 30 participants Interventional1987-05-31Completed
Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients [NCT00908674]245 participants (Actual)Observational2008-06-30Completed
Effects of Sex Steroid Hormones on Serotonin Synthesis and Degradation Measured With PET [NCT02715232]Phase 492 participants (Anticipated)Interventional2017-02-06Recruiting
Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery [NCT01973816]Phase 378 participants (Anticipated)Interventional2014-11-30Recruiting
The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants [NCT02027337]Phase 4200 participants (Anticipated)Interventional2013-12-31Recruiting
A Dose-ranging Clinical Trial to Study the Efficacy and Safety of DR-2031 for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients [NCT00196339]Phase 2315 participants (Actual)Interventional2005-06-30Completed
Institute of HIV Research and Innovation (IHRI) [NCT04590417]20 participants (Actual)Interventional2020-10-01Active, not recruiting
The Effects of Treatment With Oral Contraceptive Pill Containing Ethinyl Estradiol-Cyproterone Acetate and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in Polycystic Ovarian Syndrome [NCT02866786]Phase 4101 participants (Actual)Interventional2016-08-15Completed
Effects of Treatment With Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Serum Inflammatory Markers in Patients With Polycystic Ovary Syndrome (PCOS) [NCT02689843]Early Phase 190 participants (Actual)Interventional2018-02-01Completed
Comparative Controlled Clinical Trial of Two Pharmacological Treatments of Pedophilia [NCT00601276]Phase 348 participants (Anticipated)Interventional2007-12-31Terminated
The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives [NCT00428311]Phase 450 participants Interventional2004-04-30Completed
The Effect of Short Term Use of Finasteride Versus Cyproterone Acetate on Perioperative Blood Loss With Mono Polar Transurethral Resection of Prostate [NCT04848181]Early Phase 160 participants (Actual)Interventional2019-07-01Completed
A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer [NCT00003653]Phase 31,386 participants (Actual)Interventional1999-01-05Completed
The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization [NCT01752270]Phase 4100 participants (Anticipated)Interventional2012-12-31Not yet recruiting
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment [NCT05316935]Phase 2/Phase 3118 participants (Anticipated)Interventional2022-07-13Recruiting
Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome [NCT02460445]37 participants (Actual)Interventional2015-01-31Completed
Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial [NCT01573377]40 participants (Actual)Interventional2012-02-29Completed
A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patien [NCT00005623]Phase 30 participants Interventional1999-12-31Completed
Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 and Its Generics in Europe: An Observational Post-Authorisation Safety Study [NCT02410031]759 participants (Actual)Observational2015-06-26Completed
Evaluation of Periodontal Status and High Sensitivity C Reactive Protein Levels in Female Patients Diagnosed With Polycystic Ovary Syndrome on Cyproterone Acetate/Ethinyl Estradiol Combination Regimen: a Cross Sectional Study [NCT05021861]150 participants (Anticipated)Observational2021-11-30Not yet recruiting
Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer [NCT00363285]Phase 3900 participants (Anticipated)Interventional2003-01-31Recruiting
Functional Study of the Hypothalamus in High-resolution Magnetic Resonance Imaging (MRI) in Women With Polycystic Ovary Syndrome (PCOS): a Comparative Study [NCT03043924]52 participants (Anticipated)Interventional2017-09-26Active, not recruiting
Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases [NCT02349399]26,065 participants (Actual)Observational2015-05-01Completed
The Efficacy and Safety Study of Tung's Acupuncture for Improving Ovarian Function of Polycystic Ovarian Syndrome: a Randomised Controlled Trial [NCT02729545]Phase 260 participants (Actual)Interventional2016-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02729545 (9) [back to overview]Change in LH/FSH Ratio From Baseline to the 24th Week
NCT02729545 (9) [back to overview]Change in LH/FSH Ratio From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Body Mass Index (BMI) From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in FSH From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in LH From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Ovarian Volume From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Polycystic Ovary Number From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in the Number of Bleeding Events From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Total Testosterone (TT) From Baseline to the End of Treatment
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter

Change in LH/FSH Ratio From Baseline to the 24th Week

the change in LH/FSH ratio, values at the 24th week minus the values at baseline (NCT02729545)
Timeframe: baseline to the 24th week

Interventionratio (Mean)
Tung's Acupuncture-0.39
CPA/EE-0.44

[back to top]

Change in LH/FSH Ratio From Baseline to the End of Treatment

the change in LH/FSH ratio, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionratio (Mean)
Tung's Acupuncture-0.66
CPA/EE-0.96

[back to top]

Changes in Body Mass Index (BMI) From Baseline to the End of Treatment

the changes in BMI, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionkg/m^2 (Mean)
Tung's Acupuncture-0.90
CPA/EE-0.44

[back to top]

Changes in FSH From Baseline to the End of Treatment

changes in follicle-stimulating hormone (FSH), values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

InterventionmIU/mL (Mean)
Tung's Acupuncture-0.49
CPA/EE-0.22

[back to top]

Changes in LH From Baseline to the End of Treatment

changes in luteinizing hormone(LH), values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

InterventionmIU/mL (Mean)
Tung's Acupuncture-3.92
CPA/EE-5.66

[back to top]

Changes in Ovarian Volume From Baseline to the End of Treatment

changes in ovarian volume, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventioncm^3 (Mean)
Tung's Acupuncture-1.70
CPA/EE-1.03

[back to top]

Changes in Polycystic Ovary Number From Baseline to the End of Treatment

the changes in polycystic ovary number, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionpolycystic ovaries (Mean)
Tung's Acupuncture0.00
CPA/EE0.00

[back to top]

Changes in the Number of Bleeding Events From Baseline to the End of Treatment

Changes in the number of bleeding events, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionbleeding events (Mean)
Tung's Acupuncture0.66
CPA/EE1.21

[back to top]

Changes in Total Testosterone (TT) From Baseline to the End of Treatment

changes in total testosterone (TT) , values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionnmol/L (Mean)
Tung's Acupuncture-0.67
CPA/EE-0.33

[back to top]

Pharmacokinetics Parameter

Area Under Curve from 0 to 72 hours (AUCt) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg*hr/mL (Mean)
AUC0-t of Cyproterone AcetateAUC0-t of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet127.54842.56
Elzsa Film-coated Tablet132.56870.45

[back to top]

Pharmacokinetics Parameter

Maximum plasma concentration (Cmax) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg/mL (Mean)
Cmax of Cyproterone AcetateCmax of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet16.2093.61
Elzsa Film-coated Tablet17.39103.69

[back to top]